Ewa Bryndza Tfaily, M. Cyran, R. Gendek, E. Szilagyi, Jason L Le, A. Domaszewska-Szostek, J. Cwykiel, M. Siemionow
{"title":"2594: In vitro and in vivo characterization of human hematopoietic chimeric cells - A novel strategy to induce tolerance in transplantation","authors":"Ewa Bryndza Tfaily, M. Cyran, R. Gendek, E. Szilagyi, Jason L Le, A. Domaszewska-Szostek, J. Cwykiel, M. Siemionow","doi":"10.1080/23723505.2016.1234208","DOIUrl":null,"url":null,"abstract":"2594: In vitro and in vivo characterization of human hematopoietic chimeric cells A novel strategy to induce tolerance in transplantation Ewa Bryndza Tfaily, PhD, Malgorzata Cyran, MD, Rafal Gendek, MD, PhD, Erzsebet Szilagyi, MD, PhD, Jason Le, MD, Anna Domaszewska-Szostek, PhD, Joanna Cwykiel, MSc, and Maria Siemionow, MD, PhD, DSc University of Illinois at Chicago, Chicago, IL, USA; Polish Academy of Science, Warszawa, Poland Background Cell-based therapies represent a new promising approach for tolerance induction in transplantation One of the methods for immune response modulation in solid organ and vascularized composite allograft (VCA) recipients is donor bone marrow (BM) transplantation We propose a new cellular therapy based on application of the ex vivo created donor-recipient chimeric cells as an alternative approach to BM-based therapies in support of solid organ and VCA transplantation The aim of this study was further characterization of human hematopoietic chimeric cells (HHCC).","PeriodicalId":372758,"journal":{"name":"Vascularized Composite Allotransplantation","volume":"19 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2016-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vascularized Composite Allotransplantation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/23723505.2016.1234208","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
2594: In vitro and in vivo characterization of human hematopoietic chimeric cells A novel strategy to induce tolerance in transplantation Ewa Bryndza Tfaily, PhD, Malgorzata Cyran, MD, Rafal Gendek, MD, PhD, Erzsebet Szilagyi, MD, PhD, Jason Le, MD, Anna Domaszewska-Szostek, PhD, Joanna Cwykiel, MSc, and Maria Siemionow, MD, PhD, DSc University of Illinois at Chicago, Chicago, IL, USA; Polish Academy of Science, Warszawa, Poland Background Cell-based therapies represent a new promising approach for tolerance induction in transplantation One of the methods for immune response modulation in solid organ and vascularized composite allograft (VCA) recipients is donor bone marrow (BM) transplantation We propose a new cellular therapy based on application of the ex vivo created donor-recipient chimeric cells as an alternative approach to BM-based therapies in support of solid organ and VCA transplantation The aim of this study was further characterization of human hematopoietic chimeric cells (HHCC).
2594:人造血嵌合细胞的体外和体内特性诱导移植耐受的新策略Ewa Bryndza Tfaily, PhD, Malgorzata Cyran, MD, Rafal Gendek, MD, PhD, Erzsebet Szilagyi, MD, PhD, Jason Le, MD, Anna Domaszewska-Szostek, PhD, Joanna Cwykiel, MSc, and Maria Siemionow, MD, PhD, DSc University of Illinois at Chicago, Chicago, IL, USA;波兰科学院,华沙,在实体器官和血管化复合同种异体移植(VCA)受者中,免疫反应调节的方法之一是供体骨髓(BM)移植。我们提出了一种基于体外创造的供体-受体嵌合细胞的新细胞治疗方法,作为支持实体器官和VCA移植的基于骨髓治疗的替代方法本研究进一步表征了人造血嵌合细胞(HHCC)。